BRD0639 is a first-in-class PBM-competitive small molecule inhibitor that disrupts the PRMT5-RIOK1 complex with IC50s of 7.5 μM and 16 μM in permeabilized and living cells, respectively.
research use only
Cat.No.E1007
| Related Targets | HDAC JAK BET Histone Methyltransferase PKC PARP HIF EZH2 AMPK Histone Acetyltransferase |
|---|---|
| Other PRMT Inhibitors | LLY-283 GSK3326595 (Pemrametostat, EPZ015938) C7280948 GSK3368715 3HCl TC-E 5003 Furamidine dihydrochloride LLY-284 TNG-462 AMG 193 MS023 hydrochloride |
|
In vitro |
DMSO
: 95 mg/mL
(199.6 mM)
Ethanol : 95 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 475.948 | Formula | C21H22ClN5O4S |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2760881-74-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | Smiles | CC(N1N=CC(=CC1=O)Cl)C(=O)NC2=CC=C(C)C(=C2)[S](=O)(=O)NCCC3=NC=CC=C3 | ||
| Targets/IC50/Ki |
PRMT5-RIOK1 complex
(in permeabilized cells) 7.5 μM
PRMT5-RIOK1 complex
(in permeabilized cells) 16 μM
|
|---|---|
| In vitro |
BRD0639, which engages the target in Expi293 cells, disrupts PRMT5−RIOK1 complexes, and reduces substrate methylation. This compound also reduces SDMA in the same subset of proteins affected by genetic perturbation of the PBM binding site. |
References |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.